Objective:To observe the effect of bortezomib combined with chemotherapy in patients with relapsed and refractory acute lymphoblastic leukemia(ALL). Methods:Three cases of relapsed and refractory ALL were treated with bortezomib(1.3 mg·m-2 dose, day 1,4,8,11) in combination with DOLP(doxorubicin 60 mg·m-2 dose, day 1 to 3, vincristine 2 mg dose, day 1,8,15,22, L-asparaginase 2 000 IU·m-2 dose, day 2,8,15,21, dexamethasone 10 mg dose, day 1 to 14), One case of relapsed and refractory ALL was treated with bortezomib (1.3 mg·m-2 dose, day 1,4,8,11) in combination with COMEP (cyclophosphamide 750 mg·m-2 dose, day 1,3, mitoxantrone 4 mg dose, day 1 to 4, dexamethasone 10 mg dose, day 1 to 14, etoposide 0.1 g dose, day 1 to 4, vincristine 2 mg dose, day 1,8,15,22). The curative effects by peripheral blood, bone marrow cell morphology, immunophenotyping, cytogenetics, and detected NFκB expression level before and after chemotherapy were evaluated. Results:2 cases of 3 cases who received bortezomib combined with DOLP regimen had complete remission with a course of chemotherapy, 1 case had partial remission, 1 case who received bortezomib combined with COMEP regimen did not have response with one course of chemotherapy. Conclusion:Bortezomib combined with chemotherapy and targeted therapy drugs can provide new strategies for the treatment of relapsed and refractory ALL.
 ZHAO J,WANG C,SONG Y,et al.Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy[J].Int J Gen Med,2015,12(8):211-214.
 DEWAR R,CHEN S T,YECKES-RODIN H,et al.Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker[J].Cancer Biol Ther,2011,11(6):552-558.
 HU X,XU J,SUN A,et al.Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity[J].Leuk Lymphoma,2011,52(12):2393-2395.
 KANE R C,BROSS P F,FARRELL A T,et al.Velcade:U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy[J].Oncologist,2003,8(6):508-513.
 HOUGHTON P J,MORTON C L,KOLB E A,et al.Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program[J].Pediatr Blood Cancer,2008,50(1):37-45.
 WALKER A R,KLISOVIC R B,GARZON R,et al.Phase Ⅰ study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia[J].Leuk Lymphoma,2014,55(6):1304-1308.
 MESSINGER Y H,GAYNON P S,SPOSTO R,et al.Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia:therapeutic advances in childhood leukemia & lymphoma (TACL) study[J].Blood,2012,120(2):285-290.
 CORTES J,THOMAS D,KOLLER C,et al.Phase I study of bortezomib in refractory or relapsed acute leukemias[J].Clin Cancer Res,2004,10(10):3371-3376.
 KOYAMA D,KIKUCHI J,HIRAOKA N,et al.Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia[J].Leukemia,2014,28(6):1216-1226.
 BASTIAN L,HOF J,PFAU M,et al.Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53,PI3K/AKT,and NF-κB[J].Clin Cancer Res,2013,19(6):1445-1457.
 ROMANO M F,PETRELLA A,BISOGNI R,et al.Effect of NF-kappaB/Rel inhibition on spontaneous vs chemotherapy-induced apoptosis in AML and normal cord blood CD34+ cells[J].Leukemia,2003,17(6):1190-1192.
 MIN D J,MOSKOWITZ N P,BROWNSTEIN C,et al.Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines[J].Apoptosis,2006,11(11):1977-1986.
 WANG Z,ZHU S,ZHANG G,et al.Inhibition of autophagy enhances the anticancer activity of bortezomib in B-cell acute lymphoblastic leukemia cells[J].Am J Cancer Res,2015,5(2):639-650.